[1]
Gansevoort, R.T., Arici, M. and Benzing, T. 2021. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. KIDNEYS. 3.17 (Sep. 2021), 34–38. DOI:https://doi.org/10.22141/2307-1257.3.17.2016.76538.